Search

Author/Creator Li, Y.

4. 104P Camrelizumab combined with chemotherapy and apatinib as first-line therapy for extensive-stage small cell lung cancer: A phase II single-arm, exploratory research. (December 2022)

Authors:
Zhao, Y.; Wang, X.; Zhang, M.; Liu, J.; Pu, H.; Li, X.; Zhao, H.; Xu, S.; Yang, M.; Bai, S.; Guo, L.; Zhao, L.; Li, Y.; Wang, Y.
Journal:
Immuno-oncology technology
Issue:
Volume 16(2022)Supplement 1
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

7. 136P Tislelizumab (TIS) plus chemotherapy (chemo) for EGFR-mutated non-squamous non-small cell lung cancer (nsq-NSCLC) failed to EGFR tyrosine kinase inhibitors (TKIs) therapies: The primary analysis. (December 2022)

Authors:
Han, B.; Zhong, H.; Tian, P.; Zhao, Y.; Guo, Q.; Yu, X.; Yu, Z.; Zhang, X.; Li, Y.; Chen, L.; Zhang, Y.; Shi, X.; Wang, J.
Journal:
Immuno-oncology technology
Issue:
Volume 16(2022)Supplement 1
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

10. 1: Circulating tumour cells from small cell lung cancer patients are tumourigenic. (January 2015)

Authors:
Hodgkinson, C.; Morrow, C.; Tugwood, J.; Li, Y.; Metcalf, R.; Rothwell, D.; Trapani, F.; Burt, D.; Simpson, K.; Morris, K.; Pepper, S.; Nonaka, D.; Greystoke, A.; Kelly, P.; Bola, B.; Polanski, R.; Krebs, M.; Antonello, J.; Ayub, M.; Faulkner, S.
Journal:
Lung cancer
Issue:
Volume 87(2015)Supplement 1
Page Start:
S1
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗